Paratek Pharmaceuticals, Inc. - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - March 30, 2012

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Paratek Pharmaceuticals, Inc.Financial_Report.xls
10-K - FORM 10-K - Paratek Pharmaceuticals, Inc.d283543d10k.htm
EX-32.1 - CERTIFICATION OF THE COMPANY'S CEO AND CFO PURSUANT TO SECTION 906 - Paratek Pharmaceuticals, Inc.d283543dex321.htm
EX-31.2 - CERTIFICATION OF THE COMPANY'S CFO PURSUANT TO SECTION 302 - Paratek Pharmaceuticals, Inc.d283543dex312.htm
EX-10.30 - FIRST AMENDMENT TO THE UNITED STATES LICENSE AND COLLABORATION AGREEMENT - Paratek Pharmaceuticals, Inc.d283543dex1030.htm
EX-31.1 - CERTIFICATION OF THE COMPANY'S CEO PURSUANT TO SECTION 302 - Paratek Pharmaceuticals, Inc.d283543dex311.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

 

  (1) Registration Statement (Form S-3 No. 333-145840) and related Prospectus of Novacea, Inc.;

 

  (2) Registration Statement (Form S-3 No. 333-167598) and the related Prospectus of Transcept Pharmaceuticals, Inc.; and

 

  (3) Registration Statements (Forms S-8 No. 333-135506, No. 333-150869, No. 333-157927, No. 333-157929, No. 333-160222, No. 333-164468, and No. 333-172041) pertaining to, the Novacea, Inc. 2006 Incentive Award Plan and the Amended 2001 Stock Option Plan of Novacea, Inc., the Novacea, Inc. 2006 Incentive Award Plan, the Transcept Pharmaceuticals, Inc. 2006 Incentive Award Plan, the Transcept Pharmaceuticals, Inc. Amended and Restated 2002 Stock Option Plan, the Transcept Pharmaceuticals, Inc. 2009 Employee Stock Purchase Plan, the Transcept Pharmaceuticals, Inc. 2006 Incentive Award Plan, and the Transcept Pharmaceuticals, Inc. Amended and Restated 2006 Incentive Award Plan;

of our report dated March 30, 2012, with respect to the consolidated financial statements of Transcept Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) of Transcept Pharmaceuticals, Inc. for the year ended December 31, 2011.

/s/ Ernst & Young LLP

Redwood City, California

March 30, 2012

Paratek Pharmaceuticals, Inc. Reports